DS
BIOA

David Shaw’s BioAge Labs BIOA Stock Holding History

David Shaw’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Buy
742,761
+43,571
+6% +$787K 0.01% 1346
2026
Q1 		$12.2M Buy
699,190
+359,281
+106% +$6.92M 0.01% 1476
2025
Q4 		$4.5M Buy
339,909
+235,628
+226% +$2.09M ﹤0.01% 2397
2025
Q3 		$613K Buy
104,281
+36,883
+55% +$173K ﹤0.01% 3754
2025
Q2 		$278K Buy
+67,398
New +$272K ﹤0.01% 3916

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

David Shaw's BIOA Position: Q2 2026 in Review

David Shaw increased its BioAge Labs (BIOA) stake by 6.2% in Q2 2026, buying an estimated $787K and bringing the position to 742,761 shares worth $18.2M. The position accounts for 0.01% of the portfolio, ranked #1346.

David Shaw first reported a position in BIOA in Q2 2025 and has held it in 5 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • David Shaw held 742,761 shares of BioAge Labs worth $18.2M as of Q2 2026.
  • David Shaw bought 43,571 BioAge Labs shares in Q2 2026, an estimated $787K.
  • BioAge Labs made up 0.01% of David Shaw's portfolio in Q2 2026, its #1346 holding.
  • David Shaw first reported a position in BioAge Labs in Q2 2025 and has held it in 5 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.